Physician profile
Arun K Sachdev
NPI 1578547170
$7,466.14
in general payments reported to CMS, 2019-2025
28 companies · $517 in 2025
The $517 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,050 · 2020: $885 · 2021: $1,300 · 2022: $1,481 · 2023: $1,364 · 2024: $869 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,749.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,617.91 | 2019-2024 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,157.08 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,034.15 | 2019-2025 | Tremfya, Stelara, Remicade |
| Gilead Sciences, INC. | $622.00 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.54 | 2019-2023 | Xifaxan, Trulance |
| Pfizer INC. | $231.12 | 2019-2021 | |
| Celgene Corporation | $231.11 | 2021-2024 | Zeposia |
| Genzyme Corporation | $169.48 | 2023-2024 | |
| Allergan, INC. | $168.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $149.52 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $120.05 | 2022 | |
| Qol Medical, LLC | $84.57 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $79.86 | 2020-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $78.67 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $45.64 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $36.94 | 2020 | |
| Aimmune Therapeutics, INC. | $35.40 | 2024-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $34.89 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $32.37 | 2022-2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $31.84 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $31.46 | 2021 | |
| Endo Pharmaceuticals INC. | $30.56 | 2020 | |
| Ucb, INC. | $29.13 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.56 | 2020 | |
| Fresenius Kabi USA, LLC | $16.10 | 2023 | |
| Ironwood Pharmaceuticals, INC | $15.70 | 2024 | |
| Olympus America INC. | $13.89 | 2019 | |
| Redhill Biopharma INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.